Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical Studies

Procalcitonin as a biomarker for ventilator associated pneumonia in COVID-19 patients: Is it an useful stewardship tool?

Marina Farrel Cortes, Bianca Leal de Almeida, Evelyn Patricia Sanchez Espinoza, Aleia Faustina Campos, Maria Luiza do Nascimento Moura, Matias C. Salomao, Icaro Bosczowski, Maristela Pinheiro Freire, Laina Bubach de Carvalho, Glauzia Paranhos-Baccalab, Silvia Figueiredo Costa, Thais Guimaraes

Department of Infection Diseases, LIM-49, Instituto de Medicina Tropical, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

Open Innovation and Partnership Department at bioMerieux, Sao Paulo, Brazil

Instituto de Medicina Tropical, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

ARTICLE INFO

Article history:
Received 13 November 2020
Revised in revised form 4 February 2021
Accepted 9 February 2021
Available online 12 February 2021

Keywords:
COVID-19
Procalcitonin
Ventilator Associated Pneumonia
Secondary infection
SARS-CoV-2 pandemic

ABSTRACT

Ventilator associated pneumonia (VAP) is a severe complication that can lead to high mortality when not early identified or when therapy is delayed. The aim of this study was to evaluate procalcitonin (PCT) as a biomarker for VAP development. In total, 73 hospitalized patients with COVID-19 were analyzed. PCT levels greater than 0.975 ng/mL were more related to VAP. No association was found for C-reactive protein (CRP). The results show that procalcitonin may be a pertinent biomarker for VAP diagnosis and can be a helpful tool for antibiotic withdrawal.

1. Introduction

Coronavirus disease 2019 (COVID-19) is a pandemic caused by SARS-CoV-2 that already exceeded 30 million confirmed cases (World Health Organization 2020). This virus can cause acute respiratory distress syndrome (ARDS), an acute life-threatening condition characterized by hypoxemia and pulmonary alterations. Mechanical ventilation (MV), extra corporeal membrane oxygenation (ECMO) and prone position are common supportive measures of this disorder. However, MV can lead to ventilator associated pneumonia (VAP), a severe complication which, when not identified early on or when empiric therapy is delayed, represents a threat. VAP is a pulmonary infection that can occur after 48h of MV and is responsible for increasing hospitalization time by 11.5 to 13.1 days (IDSA VAP Guideline, 2017) and, therefore, costs (Safdar et al., 2005). The patient’s mortality ranges from 20% to 50% (Kalil et al., 2017). The importance of VAP prevention, as well as its early diagnostic, is reinforced in COVID-19 patients due to the immunological and inflammatory profile of severe cases and the prolonged length ICU stay (Povoa et al., 2020). The clinical features of COVID-19 pneumonia present usually as high fever, severe hypoxemia, hyperleukocytosis, biological inflammatory syndrome and extensive bilateral radiologic alterations. VAP diagnosis in critical COVID-19 patients is a challenge once both share similar symptoms and differential by pulmonary imaging may be challenging. Therefore, usual characteristics for VAP diagnosis are not applicable in critical COVID-19 patients (Francois et al., 2020). As a result, the urgency of discovering new VAP biomarkers becomes extremely necessary. Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin, involved with calcium homeostasis. PCT is a prohormone synthesized in several tissues. In healthy patients, only the procalcitonin produced in the thyroid has a proper physiological function, participating in calcium homeostasis. PCT is a prohormone synthesized in several tissues. In healthy patients, only the procalcitonin produced in the thyroid has a proper physiological function, participating in calcium homeostasis. In patients with several acute events, mainly infections, it is elevated, and serves as an instrument to assist the risk stratification (Jekarl et al., 2019) of early diagnosis of VAP in hospitalized patients. The aim of this study was to evaluate procalcitonin as a biomarker for VAP development at intensive care units (ICU) (Fig. 1).

2. Methods

Hospital das Clinicas is a tertiary university hospital and the reference center for COVID-19 patients in the state of Sao Paulo, Brazil.
This study is a cohort involving 73 patients hospitalized between April and June 2020 with a confirmed diagnostic for SARS-CoV-2 by RT-PCR and with a suspected secondary infection. This work was accepted by the research ethics committee; number 4.360.588. Daily visits to discuss ICU cases and the use of antibiotics was conducted by the infection control team of the hospital comprising 8 infectious diseases physicians. The patients were classified as having a secondary healthcare associated infection (HCAI) and VAP using CDC criteria. If the patient met the secondary infection criteria, a PCT sample was collected on day 1 and the other two subsequent days. Antimicrobial treatment was empirically administered based on local data and was discontinued according to the patients clinic and if the PCT value was less than 0.5 in at least two samples. Endotracheal aspirate and blood cultures were also collected. Data regarding clinical and demographic characteristics, including comorbidities, antibiotics and laboratory tests were collected from electronic medical records. Blood was collected using tube Gel BD Vacutainer SST® (BD, New Jersey, EUA). Tubes were centrifuged at 3000 rpm for 10min and PCT levels were measured in the serum using VIDAS® B.R.A.H.M.S PCT™ (BioMérieux, Marcy l’Etoile, France). Data was analyzed using epiinfo (CDC Epinfo 7.2) and ROC curve was designed using Graphpad prism 5. Categorical variables were presented as absolute numbers and percentages, and continuous variables as median. Univariable associations between demography and biomarkers levels and VAP were tested. Statistical tests were two tailed, 95% confidence intervals were calculated using the exact binomial method; with a significance level of 0.05.

3. Results

A total of 73 patients admitted at ICU with a positive COVID-19 test were analyzed (Table 1). Among these, 28 (38%) evolved with VAP. Gender, age and ethnicity was equally distributed between VAP and non VAP group. The most frequent comorbidity was hypertension (52%) followed by diabetes (35.6%) and obesity (16.4%). Among all exams analyzed, only PCT presented significance (P = 0.0010) between VAP and non-VAP group. Both groups had similar mortality score, Simplified Acute Physiology Score III (SAPS3) and days on MV. The most commonly isolated microorganisms in blood were gram positive with coagulase-negative staphylococci being the most frequent, isolated in 23.3% of patients. Gram negative bacteria

Table 1.

Clinical and demographic characteristics of COVID-19 patients of this study.

| Details                              | Total (n = 73) | VAP (n = 28) | Non-VAP (n = 45) | P value | RR IC95% |
|--------------------------------------|---------------|-------------|-----------------|---------|---------|
| Age                                  |               |             |                 |         |         |
| Years                                | 58            | 59 (25-87)  | 58 (16-89)      | 0.83    | -       |
| Sex                                  |               |             |                 |         |         |
| Female                               | 35 (48%)      | 12 (42.8%)  | 23 (51%)        | 0.25    | 0.88    |
| Male                                 | 38 (52%)      | 16 (57.2%)  | 22 (49%)        |         |         |
| Ethnicity                            |               |             |                 |         |         |
| White                                | 36 (49%)      | 15 (53.6%)  | 21 (46.7%)      | 0.63    | 1.2     |
| Black                                | 16 (22%)      | 5 (17.8%)   | 11 (24%)        | 0.57    | 0.77    |
| Brown                                | 19 (26%)      | 7 (25%)     | 12 (27%)        | 1       | 0.96    |
| Ignored                              | 2 (3%)        | 1 (3.6%)    | 1 (2.3%)        | 1       | 1.31    |
| Outcome                              |               |             |                 |         |         |
| Death                                 | 44 (60.3%)    | 20 (71.4%)  | 24 (53.3%)      | 0.07    | 1.3     |
| Comorbidities                        |               |             |                 |         |         |
| Hypertension                         | 38 (52%)      | 15 (53.6%)  | 23 (51%)        | 0.42    | 1.04    |
| Asthma                               | 1 (1.4%)      | 0           | 1 (2.2%)        | 0.30    | 0.61    |
| Diabetes                             | 26 (35.6%)    | 10 (35.7%)  | 16 (35.6%)      | 0.49    | 1.00    |
| Obesity                              | 12 (16.4%)    | 5 (17.8%)   | 7 (15.5%)       | 0.39    | 1.07    |
| Neoplasm                             | 2 (2.7%)      | 1 (3.6%)    | 1 (2.2%)        | 0.38    | 1.24    |
| Neoplasm solid organ                 | 4 (5.5%)      | 2 (7.1%)    | 2 (4.4%)        | 0.33    | 1.24    |
| Others                               | 25 (34.2%)    | 8 (28.6%)   | 16 (35.5%)      |         |         |
| Mortality score                      |               |             |                 |         |         |
| Admission SAPS3                      | 60 (81.7%)    | 44 (22)     | 16 (33.3%)      |         |         |
| Days of MV                           | 21 (3-81)     | 22 (9-61)   | 20 (3-81)       | 0.22    | -       |
| Exams                                |               |             |                 |         |         |
| D-dimer (ng/mL)                      | 7517 (6545-77101) | 7719 (190-65626) | 7411 (1005-77101) | 0.82    | -       |
| CRP (mg/L)                           | 343 (56-988)  | 331 (118-8907) | 351 (56-988)    | 0.82    | -       |
| PCT (ng/mL)                          | 5 (0.06-35.48) | 7 (0.13-35.26) | 3.8 (0.06-35.4) | 0.001   | -       |
| Leucocytes (x10^3/mm^3)              | 17.311 (100-95700) | 18.0907 (100-55110) | 16.826 (2305-95700) | 0.41    | -       |
| Neutrophils (x10^3/mm^3)             | 14.926 (1929-83259) | 16.2094 (5542-50150) | 14.156 (1929-83259) | 0.29    | -       |
| Lymphocytes (x10^3/mm^3)             | 1389 (139-6791) | 1277.5 (205-6791) | 1456 (139-5742) | 0.17    | -       |
| Gram                                 |               |             |                 |         |         |
| Gram +                               | 32 (43.8%)    | 17 (60.7%)  | 15 (33.3%)      | 0.34    | 1.08    |
| Gram -                               | 21 (28.3%)    | 20 (71.4%)  | 1 (2.2%)        | 0.03    | -       |
| Agents isolated in blood culture     |               |             |                 |         |         |
| Coagulase-negative staphylococci     | 16 (22%)      | 6 (21.4%)   | 10 (22.2%)      | 0.47    | 0.98    |
| S. aureus                            | 5 (6.8%)      | 2 (7.1%)    | 3 (6.7%)        | 0.46    | 1.03    |
| P. aeruginosa                        | 1 (1.4%)      | 1 (3.6%)    | 0              | 0.19    | -       |
| K. pneumoniae                        | 2 (2.7%)      | 2 (7.1%)    | 0              | 0.07    | -       |
| Candida spp.                         | 3 (4.1%)      | 2 (7.1%)    | 1 (2.2%)        | 0.19    | 1.88    |
| Enterococcus spp.                    | 3 (4.1%)      | 2 (7.1%)    | 1 (2.2%)        | 0.19    | 1.88    |
| Antibiotic                           |               |             |                 |         |         |
| Metoprenen                           | 45 (61.6%)    | 19 (67.8%)  | 26 (57.8%)      | 0.20    | 1.17    |
| Vancomycin                           | 44 (60.3%)    | 17 (60.7%)  | 27 (60%)        | 0.48    | 1.01    |
| Piperacillin/Tazobactam              | 41 (56.2%)    | 14 (50%)    | 27 (60%)        | 0.21    | 0.85    |
| Colistin                             | 25 (34.2%)    | 12 (42.8%)  | 13 (28.9%)      | 0.12    | 1.28    |
| Others                               | 30 (41%)      | 14 (50%)    | 16 (35.5%)      | 0.12    | 1.26    |

VAP = ventilator associated pneumonia.
were significantly more isolated in VAP patients ($P = 0.0003$). The most frequently isolated microorganism in blood was Coagulase-negative staphylococci (22%) followed by S. aureus (6.8%), Candida spp. (4%) and K. pneumoniae (2.7%). In tracheal secretion, P. aeruginosa was isolated in 6 patients (8.2%) followed by S. aureus (6.8%), A. baumannii (5.5%) and K. pneumoniae (5.5%). The most used antibiotic in general were ceftriaxone (69.8%) followed by meropenem (61.6%), vancomycin (60.3%), piperacillin/tazobactam (56.2%), azithromycin (37%) and colistin (34.2%). In VAP, 67.8% of patients used meropenem, 60.7% used vancomycin, 50% piperacillin/tazobactam and 42.8% used colistin. Antibiotic treatment was withdrawn in 12% of patients, and it is important to note that the mean PCT values in these patients were significantly lower than those who did not (0.42 ng/mL and 5.72 ng/mL, respectively $P = 0.002$). On the other hand, C-reactive protein (CRP) values were not significantly different (295 mg/L and 350 mg/L, $P = 0.21$). The ROC curve comparing PCT levels with VAP diagnosis showed that levels of PCT greater than 0.975 ng/mL are more related to VAP with the accuracy of 71% ($P = 0.002$).

4. Discussion

Here we analyzed clinical data and procalcitonin dosage of 73 COVID-19 hospitalized patients to evaluate PCT as an aid biomarker for VAP diagnosis. Despite the fact that the risk of developing VAP is increased with longer MV, the media of days with MV was a not significantly different between VAP and non-VAP group in this study. Among the exams analyzed in this study, PCT was the only one significantly different from the two groups with a cutoff of 0.975 ng/mL to indicate probable VAP. Indeed, serum PCT levels are increased in bacterial infections so it can be used as a biomarker to differentiate them from viral infections or, in this case, as an indicator of coinfection. Still, based on SEPSIS-3 PCT can be used as a prognostic marker of sepsis and predict mortality in hospitalized patients (Jekarl et al., 2019). In addition, increased PCT levels are associated with higher risk of severe infection in patients with COVID-19 (Lippi and Plebani, 2020). A study involving experts with a background in intensive care medicine and clinical microbiology indicated that VAP diagnosis should be based on chest X-ray, blood cultures, endotracheal aspirate, CRP or PCT, and gram stain. Additionally, the authors indicated PCT as the biomarker with most impact on patient outcomes (Ferreira-Coimbra et al., 2020). In this study, PCT values were also positively associated to antibiotic withdrawal ($P = 0.002$), while CRP levels did not ($P = 0.21$). Nevertheless, more studies are needed to assess the usefulness of PCT for withdrawal of antibiotics. No differences in the classes of antibiotic prescription was significantly found. Ceftriaxone and azithromycin were not analyzed once they are not antibiotics used to treat VAP. The increase in the use of antibiotics during COVID-19 pandemic is worrying because it can stimulate bacterial resistance even more (Canton et al., 2020). Indeed, PCT dosage in combination with a rapid multiplex PCR respiratory panel can optimize the use of antibiotic in patients with severe acute respiratory infection preventing antibiotic resistance and misuse and therefore avoiding additional costs (Lee et al., 2020). As stewardship during the pandemic it has been recommending to not use antibiotic prophylactically and to descaled and stop antibiotic as soon as possible. This further emphasizes the importance of finding reliable markers to ensure antibiotic prevention and withdrawal. This study has limitation as be uncenter, the limited size of population and that PCT was not available to COVID patients without a suspect secondary infection. In conclusion, procalcitonin seems to be a pertinent biomarker for VAP diagnosis and can be a helpful tool for antibiotic withdrawal. Therefore, PCT measurement may indeed play a role in the prognosis of severe COVID-19.

Authors' contributions

Marina Farrel Córtes, conception of the work, analysis, interpretation of data, writing and revising; Bianca Leal de Almeida, conception of the work, writing and revising; Evelyn Patricia Sanchez Espinoza, conception of the work, analysis, writing and revising; Alea Faustina Campos, conception of the work; Maria Luiza do Nascimento Moura, Acquisition of data Matias C. Salomão2, Acquisition of data; Icaro Bosczvoski, Acquisition of data; Maristela Pinheiro Freire, Acquisition of data; Laine Bubach de Carvalho, Acquisition of data; Glaucia Paranhos Baccala, Acquisition of data, writing and revising; Silvia Figueredo Costa, study design, acquisition of data, writing, and revising; Thais Guimarães, study design, acquisition of data and revising.

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest to declare.

Source of funding

This research was supported by Hospital das Clínicas, procalcitonin dosing kits were kindly donated by bioMérieux and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) funded one post doc scholarship.

References

Cantón R, Cijón D, Ruiz-Garbarajosa P. Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic. Curr Opin Crit Care 2020;26(5):433–41. doi: 10.1097/MCC.0000000000000755.

Ferreira-Coimbra J, Ardancy C, Diaz E, Leone M, De Pascale G, Póvoa P, et al. Ventilator-associated pneumonia diagnosis: a prioritization exercise based on multi-criteria decision analysis. European journal of clinical microbiology & infectious diseases: official publication of the Eur Soc Clin Microbiol 2020;39(2):281–6. doi: 10.1007/s10096-019-03720-x.

François R, Laterre PF, Luft CE, Chastre J. The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients. Crit Care 2020;24(1):289. doi: 10.1186/s13054-020-03013-2.

Jekarl DW, Lee S, Kim M, Kim Y, Woo SH, Lee WJ. Procalcitonin as a prognostic marker for sepsis based on SEPSIS-3. C J Clin Lab Anal 2019;33(9):1–7. doi: 10.1002/cjal.22996.

Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Clin Infect Dis 2017;65(12):2161. doi: 10.1093/cid/cix550.

Lee CC, Chang JC, Mao XW, Hsu WT, Chen SY, Chen YC, et al. Combining procalcitonin and rapid multiplex respiratory virus testing for antibiotic stewardship in older adult patients with severe acute respiratory infection. J Am Med Dir Assoc 2020;21(11):62–7. doi: 10.1016/j.jamda.2019.09.020.

Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta 2020;505:190–1. doi: 10.1016/j.cca.2020.03.004.

Póvoa P, Parnis GG, Iorio N. COVID-19: an alert to ventilator-associated bacterial pneumonia. Infect Dis Ther 2020;9(3):417–20. https://doi.org/10.1007/s40421-020-00306-5.

Saifdar N, Desjulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33(10):2184–93. doi: 10.1097/01.ccm.0000181731.53912.d9 PMID: 16215384.

World Health Organization. Coronavirus Disease 2019.